Summary & Overview
HCPCS C9790: Histotripsy of Malignant Renal Tissue, Image-Guided
HCPCS Level II code C9790 designates histotripsy of malignant renal tissue, an image-guided, non-thermal ablation technique that uses focused acoustic energy to mechanically disrupt tumor tissue. The code consolidates the procedural and imaging components and is relevant as novel ablation technologies enter clinical use for renal malignancies. Nationally, this code matters for coding consistency, payer coverage determinations, and integration of emerging interventional oncology procedures into outpatient care settings.
Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical indications and service context, typical sites of service where histotripsy for renal tumors is delivered, and common billing considerations tied to image-guided interventional procedures. The publication presents national benchmarks for utilization where available, summarizes recent policy and coverage trends affecting new technology codes, and outlines coding relationships relevant to procedure reporting and claims processing.
This summary is intended to orient clinical coders, revenue cycle teams, and payer policy analysts to the core clinical and billing characteristics of HCPCS Level II code C9790 for malignant renal tissue histotripsy.
Billing Code Overview
HCPCS Level II code C9790 describes histotripsy of malignant renal tissue, a non-thermal ablation procedure that uses targeted acoustic energy to mechanically fractionate tumor tissue. The code includes image guidance as part of the service.
Service Type: Image-guided, non-thermal tumor ablation
Typical Site of Service: Hospital outpatient department or ambulatory surgical center, where image-guided interventional procedures for renal malignancy are performed.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with a solitary enhancing mass in the right kidney diagnosed on contrast-enhanced CT and biopsy-proven renal cell carcinoma is scheduled for image-guided histotripsy. The patient has comorbid hypertension and chronic kidney disease stage 3, making nephron-sparing, non-thermal ablation preferable to limit renal parenchymal loss and avoid thermal injury. Pre-procedure planning includes cross-sectional imaging review, lab assessment (including coagulation profile and creatinine), informed consent, and anesthesia evaluation. On the day of service the patient is positioned in the interventional suite or hybrid operating room, ultrasound and CT are available for image guidance, and monitored anesthesia care or general anesthesia is provided per anesthesia assessment. The interventional radiologist places the histotripsy transducer into an acoustic window and delivers focused acoustic energy to mechanically fractionate the targeted malignant renal tissue while real-time imaging confirms lesion targeting and adjacent structure avoidance. Post-procedure, the patient is observed for vital sign stability, pain control, and imaging to assess immediate treatment effect and exclude complications, then discharged home the same day or admitted for overnight observation depending on clinical status.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no modifier is applicable and claim requires none. |